Inequity Unveiled: How the 2024 Access to Medicine Index Highlights Persistent Gaps in Global Health Equity

A recent article by the Rwandan media outlet Taarifa discusses the newly released report by the Access to Medicine Foundation, which evaluates the efforts of 20 major pharmaceutical companies to improve access to essential medicines in low- and middle-income countries (LMICs).

The article highlights key insight from the 2024 Access to Medicine Index, which reveals ongoing challenges in improving healthcare access, especially in LMICs. It notes that although leading companies are making efforts to bridge the gap in equitable access, no company is yet meeting its full potential.

“There are significant opportunities to scale access and finally bridge the health equity gap for billions around the world,” the article quotes Jayasree Iyer, CEO of the Foundation, “The tools exist, and so do the partnerships. What we need now is sustained commitment and deliberate action to reach those who have been left behind for far too long.”

The article also outlines opportunities for companies to bridge healthcare access gaps, as highlighted in the report. Claudia Martínez, Research Director at the Foundation, is quoted emphasising the importance of expanding clinical trial capabilities and prioritising technology transfers. These initiatives are seen as critical to addressing the ongoing disparities in access to healthcare in LMICs, with pharma companies playing a pivotal role in creating sustainable solutions.